During an interview earlier this week, NAD+ expert, Dr. Charles Brenner (FAQs) was asked whether daily consumption of vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Life Changing Anecdotes) brought cancer risk. Here’s what he said:
Month: February 2023
During a podcast interview earlier this week, Dr. Charles Brenner (FAQs) was asked about NAD+ IVs (FAQs and Anecdotes). As both an NAD+ expert, and the discoverer of Nicotinamide Riboside “NR” (FAQs) (Life Changing Anecdotes) as an NAD+ boosting vitamin, Dr. Brenner is often asked about this increasingly popular treatment. Here’s Dr. Brenner’s most recent take:
Parkinson’s expert Dr. Charalampos (Haris) Tzoulis is actively running clinical trials studying NAD+ boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Reviews) as a possible treatment option for Parkinson’s patients. He’s clearly optimistic. And, as you’ll see below, this is consistent with what we’ve heard from NAD+ experts Dr. Charles Brenner (FAQs) and Dr. David Sinclair in regards to their preferred NAD+ precursors, NR and NMN, respectively:
During the Q&A portion of last week’s presentation, Parkinson’s expert Dr. Charalampos (Haris) Tzoulis was asked if, based on his ongoing clinical trials studying vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Anecdotes), he had any advice for consumers looking to prevent neurological disorders such as Parkinson’s. Here’s what he said:
Dr. Charalampos (Haris) Tzoulis, a Parkinson’s expert, and Professor of Neurology and Neurodegeneration at the University of Bergen is currently overseeing clinical trials studying NAD+ boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Anecdotes) as a possible treatment for Parkinson’s patients. In a recent presentation, Dr. Tzoulis explained why he chose to use NR as opposed to any other NAD+ precursor:
Earlier this week, Ladenburg Thalmann, a US investment firm hosted a Healthcare Symposia. One of its guest speakers was Dr. Charalampos (Haris) Tzoulis, Professor of Neurology and Neurodegeneration at the University of Bergen and Haukeland University Hospital, Bergen Norway. Dr. Tzoulis recently completed a Phase 1 clinical trial testing vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Anecdotes) in Parkinson’s patients. Here’s how Dr. Tzoulis explained why he initiated the study:
Earlier today, Dr. Charles Brenner (FAQs) was asked whether NAD+ boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Anecdotes) might help those suffering from Myocarditis (which occurs when the heart muscle becomes inflamed). Here’s his response:
Last week, results of a clinical study were released bringing new hope for Alzheimer’s patients: “Our results indicate that treatment of AD patients with CMA (full list) can lead to enhanced cognitive functions and improved clinical parameters associated with phenomics, metabolomics, proteomics and imaging analysis.” While this is clearly encouraging news, we’re quick to defer to the expertise of those better positioned to analyze the study results to tell us what they mean. And there’s no one better than Alzheimer’s expert Dr. Rudy Tanzi — who also happens to be a passionate consumer of one of the CMAs in the latest study, Nicotinamide Riboside “NR” (FAQs) (Reviews).